Heilongjiang ZBD Pharmaceutical Co Ltd (603567) - Total Assets
Based on the latest financial reports, Heilongjiang ZBD Pharmaceutical Co Ltd (603567) holds total assets worth CN¥11.80 Billion CNY (≈ $1.73 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check total reinvestment intensity of Heilongjiang ZBD Pharmaceutical Co Ltd to assess the company's total reinvestment commitment from operating cash flow.
Heilongjiang ZBD Pharmaceutical Co Ltd - Total Assets Trend (2011–2024)
This chart illustrates how Heilongjiang ZBD Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. Explore 603567 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Heilongjiang ZBD Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Heilongjiang ZBD Pharmaceutical Co Ltd's total assets of CN¥11.80 Billion consist of 56.6% current assets and 43.4% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 8.3% |
| Accounts Receivable | CN¥4.24 Billion | 33.4% |
| Inventory | CN¥1.49 Billion | 11.7% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥1.18 Billion | 9.3% |
| Goodwill | CN¥14.82 Million | 0.1% |
Asset Composition Trend (2011–2024)
This chart illustrates how Heilongjiang ZBD Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Heilongjiang ZBD Pharmaceutical Co Ltd.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Heilongjiang ZBD Pharmaceutical Co Ltd's current assets represent 56.6% of total assets in 2024, a decrease from 57.4% in 2011.
- Cash Position: Cash and equivalents constituted 8.3% of total assets in 2024, up from 3.6% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, an increase from 4.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 33.4% of total assets.
Heilongjiang ZBD Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Heilongjiang ZBD Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
|
China | CN¥8.25 Billion |
|
Eris Lifesciences Limited
NSE:ERIS
|
India | Rs71.60 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥13.81 Billion |
|
Lotus Pharmaceutical Co Ltd
TW:1795
|
Taiwan | NT$106.15 Billion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.69 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Sun Pharma Advanced Research Company Limited
NSE:SPARC
|
India | Rs3.22 Billion |
Heilongjiang ZBD Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.76 | 2.69 | 2.66 |
| Quick Ratio | 1.33 | 2.23 | 2.24 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.70 Billion | CN¥4.70 Billion | CN¥3.75 Billion |
Heilongjiang ZBD Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Heilongjiang ZBD Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.05 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | 2.0% |
| Total Assets | CN¥12.71 Billion |
| Market Capitalization | $644.42 Million USD |
Valuation Analysis
Below Book Valuation: The market values Heilongjiang ZBD Pharmaceutical Co Ltd's assets below their book value (0.05x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Heilongjiang ZBD Pharmaceutical Co Ltd's assets grew by 2.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Heilongjiang ZBD Pharmaceutical Co Ltd (2011–2024)
The table below shows the annual total assets of Heilongjiang ZBD Pharmaceutical Co Ltd from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥12.71 Billion ≈ $1.86 Billion |
+1.98% |
| 2023-12-31 | CN¥12.47 Billion ≈ $1.82 Billion |
+6.77% |
| 2022-12-31 | CN¥11.68 Billion ≈ $1.71 Billion |
+1.47% |
| 2021-12-31 | CN¥11.51 Billion ≈ $1.68 Billion |
+12.43% |
| 2020-12-31 | CN¥10.23 Billion ≈ $1.50 Billion |
+13.48% |
| 2019-12-31 | CN¥9.02 Billion ≈ $1.32 Billion |
+10.23% |
| 2018-12-31 | CN¥8.18 Billion ≈ $1.20 Billion |
+18.82% |
| 2017-12-31 | CN¥6.89 Billion ≈ $1.01 Billion |
+7.28% |
| 2016-12-31 | CN¥6.42 Billion ≈ $939.30 Million |
+7.89% |
| 2015-12-31 | CN¥5.95 Billion ≈ $870.62 Million |
+65.08% |
| 2014-12-31 | CN¥3.60 Billion ≈ $527.39 Million |
+10.86% |
| 2013-12-31 | CN¥3.25 Billion ≈ $475.73 Million |
+52.81% |
| 2012-12-31 | CN¥2.13 Billion ≈ $311.32 Million |
+47.76% |
| 2011-12-31 | CN¥1.44 Billion ≈ $210.69 Million |
-- |
About Heilongjiang ZBD Pharmaceutical Co Ltd
Heilongjiang ZBD Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of Chinese medicines in China. It offers cardiovascular and cerebrovascular, respiratory system, orthopedics, tumors, digestive system, anti-infection, mental nerve, genitourinary, and other disease fields. The company was founded in 1996 and is based in Hulin, China.